Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Crohn's Disease

NCT01696396 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01696396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01696396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Crohn's Disease
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
December 4, 2012
Completion date
April 10, 2018
Enrollment
254 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease